Valuation : Beacon Pharmaceuticals PLC

Market Cap 25.48B 207M 178M 167M 153M 288M 19.79B 289M 1.98B 774M 9.99B 777M 761M 33.13B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 288M 248M 233M 212M 400M 27.53B 401M 2.76B 1.08B 13.9B 1.08B 1.06B 46.08B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 day-0.29%
1 week-1.89%
Current month-4.15%
1 month-4.15%
3 months+2.26%
6 months-1.52%
Current year-0.57%
1 week 103.4
Extreme 103.4
107
1 month 103.4
Extreme 103.4
110.2
Current year 96
Extreme 96
117.9
1 year 96
Extreme 96
142.4
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%-1.89%-27.17%-57.55% 195M
-2.13%-7.08%+57.60%+109.06% 1,047B
-0.61%-2.40%+49.67%+64.83% 646B
-0.58%-4.39%+19.35%+72.10% 451B
-1.52%-4.48%+35.97%+35.92% 355B
-0.71%-3.12%+20.94%+37.50% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.85%-3.69%+48.98%+66.76% 234B
-1.73%-3.04%-20.53%-54.45% 203B
-1.39%-2.19%+27.34%+87.66% 181B
Average -1.07%-2.60%+21.37%+37.33% 365.95B
Weighted average by Cap. -1.28%-3.46%+36.23%+64.37%

Financials

2024 2025
Net sales 10.7B 86.98M 74.95M 70.27M 64.15M 121M 8.31B 121M 834M 325M 4.2B 327M 319M 13.91B 12.54B 102M 87.84M 82.36M 75.18M 142M 9.74B 142M 977M 381M 4.92B 383M 374M 16.31B
Net income 521M 4.23M 3.65M 3.42M 3.12M 5.88M 405M 5.9M 40.59M 15.84M 204M 15.9M 15.55M 677M 947M 7.69M 6.63M 6.22M 5.67M 10.69M 735M 10.72M 73.74M 28.77M 371M 28.88M 28.25M 1.23B
Net Debt 10B 81.25M 70.01M 65.64M 59.92M 113M 7.77B 113M 779M 304M 3.92B 305M 298M 13B 9.96B 80.98M 69.78M 65.42M 59.72M 113M 7.74B 113M 776M 303M 3.91B 304M 297M 12.95B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
30/08/26 BDT 104.00 -0.29% 72,715
27/08/26 BDT 104.30 +0.19% 55,550
25/08/26 BDT 104.10 -0.38% 78,085
24/08/26 BDT 104.50 -1.42% 92,150
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock